Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin

Trius Announces Notice of Allowance of U.S. Patent Application Related to
Tedizolid Phosphate Combination With Daptomycin

SAN DIEGO, May 13, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX), a biopharmaceutical company focused on the discovery,
development and commercialization of innovative antibiotics for serious
infections, announced today that it has received a Notice of Allowance from
the U.S. Patent and Trademark Office (USPTO) on an application related to its
tedizolid phosphate patent portfolio. This newly allowed patent application
protects a therapeutic combination of the experimental medicine tedizolid
phosphate with a currently available antibiotic daptomycin. Data show that
together, the medicines can uniquely prevent the development of daptomycin
non-susceptible bacterial strains such as methicillin-resistant Staphylococcus
aureus (MRSA).

As detailed in the patent application, tedizolid phosphate, at concentrations
substantially below its current therapeutic dose to treat skin infections,
unexpectedly prevents the formation of daptomycin resistant mutants of
Staphylococcus aureus. Tedizolid appears to be unique in this mutant
prevention activity given that seven other medicines tested, including
linezolid, the only other drug of the same class as tedizolid, failed to show
the same mutant prevention activity.

"MRSA bacteremia is a potentially fatal disease with limited treatment
options," said Ralph Corey, M.D. Professor of Medicine and Infectious Diseases
at Duke University. "As a clinician who treats bacteremia patients, I am
concerned by the growing resistance to one of our last effective treatment
options, daptomycin, and welcome this news that tedizolid phosphate may
prevent daptomycin resistance when used in a combination therapy."

"Given the recent positive Phase 3 results of tedizolid phosphate for the
treatment of skin infections, we are eager to examine its potential, whether
alone or in combination with other medicines, for the treatment of
bacteremia," said Jeffrey Stein, Ph.D., President and Chief Executive Officer
of Trius. "Most importantly, this patent, coupled with the results of our
long-term safety studies, provide us with guidance on how best to expand the
development of tedizolid phosphate to treat patients with severe bacterial
infections requiring sustained treatment."

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational medicine, tedizolid
phosphate, is a novel antibiotic for the treatment of acute bacterial skin and
skin structure infections (ABSSSI) and serious Gram-positive infections,
including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Trius has completed two Phase 3 ABSSSI trials and has partnered with Bayer
Pharma for the development and commercialization of tedizolid phosphate
outside of the U.S., Canada and the European Union. In addition to the
Company's tedizolid phosphate clinical program, Trius has initiated
IND-enabling studies for its Gyrase-B development candidate with potent
activity against Gram-negative bacterial pathogens including
multidrug-resistant strains of E. coli, Klebsiella, Acinetobacter and
Pseudomonas. For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding Trius' ability to
successfully complete its planned development programs, the potential of
tedizolid to effectively treat bacteremia alone and in combination with other
drugs and Trius' ability to initiate a development program in bacteremia.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the accuracy of Trius' estimates regarding expenses,
future revenues and capital requirements; the success and timing of Trius'
preclinical studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Trius' plans to develop and
commercialize its product candidates; Trius' ability to obtain additional
financing; Trius' ability to obtain and maintain intellectual property
protection for its product candidates; and the loss of key scientific or
management personnel. These and other risks and uncertainties are described
more fully in Trius' most recently filed SEC documents, including its Form
10-K, Forms 10-Q and other documents filed with the United States Securities
and Exchange Commission, including those factors discussed under the caption
"Risk Factors" in such filings. All forward-looking statements contained in
this press release speak only as of the date on which they were made. Trius
undertakes no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507
 
Press spacebar to pause and continue. Press esc to stop.